Staphylococcus lugdunensis infective endocarditis: a multicentre international observational study.
Benjamin Lefevre, Gilbert Habib, Bruno Hoen...
https://pubmed.ncbi.nlm.nih.gov/40952378Actively Recruiting
Age: 18Years +
All Genders
ID03272724
French National Observatory on Infective Endocarditis
Led by Central Hospital, Nancy, France · Updated on 2025-09-23
5000
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
C
Central Hospital, Nancy, France
Lead Sponsor
B
Bichat Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to create a national database of infective endocarditis by collecting detailed information from volunteer medical centers across the country. It focuses on describing the clinical, microbiological, therapeutic, and progression aspects of infective endocarditis, analyzing risk factors and prognosis, and comparing real-world drug and surgical treatments. Data collected includes clinical characteristics such as heart disease history, symptoms, and complications; biological and microbiological details like microorganism identification and antibiotic sensitivity; echocardiographic features; and treatment details including antibiotic and surgical interventions. All information is recorded using standardized electronic case report forms by physicians during patient hospitalization. Participants will have their medical history, biological markers, imaging, and treatment data collected and monitored throughout hospitalization. Researchers will evaluate factors like heart disease history, infection origin, clinical symptoms, biological and microbiological outcomes, imaging results, and treatments from inclusion to recovery. Optional biological sample collection may also occur. The study is ongoing with data collected since 1991, led by Central Hospital, Nancy, France.
CONDITIONS
Brief Title
French National Observatory on Infective Endocarditis
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Major Patient
- Supported in one of the participating centers
- Diagnostic classification criteria of Duke modified by Li applied after data collection
- Patients meeting criteria for definite or possible endocarditis included
- Registered with the French social security system
You will not qualify if you...
- Patient refusal to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - From inclusion to recovery
Participants undergo diagnostic assessments including clinical, biological, microbiological, and imaging evaluations to describe the history and characteristics of infective endocarditis.
Long-term Monitoring
Duration - From inclusion to recovery
Participants are observed during hospitalization to monitor the evolution of infective endocarditis including therapeutic management and outcomes.
Trial Site Locations
Total: 1 location
1
CHRU
Vandœuvre-lès-Nancy, France, 54511
Actively Recruiting
Loading map...
Research Team
N
Nadine JUGE, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
[Complications and prognosis of infective endocarditis].
Christine Selton-Suty, François Goehringer, Clément Venner...
https://pubmed.ncbi.nlm.nih.gov/31056233[Treatment of infectious endocarditis].
Bruno Hoen, Mazen Elfarra, Olivier Huttin...
https://pubmed.ncbi.nlm.nih.gov/31109766Time interval between infective endocarditis first symptoms and diagnosis: relationship to infective endocarditis characteristics, microorganisms and prognosis.
Yohan N'Guyen, Xavier Duval, Matthieu Revest...
https://pubmed.ncbi.nlm.nih.gov/27607562Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study.
B Lefèvre, B Hoen, F Goehringer...
https://pubmed.ncbi.nlm.nih.gov/34383175Impact of referral bias on prognostic studies outcomes: insights from a population-based cohort study on infective endocarditis.
Magali Collonnaz, Marie-Line Erpelding, François Alla...
https://pubmed.ncbi.nlm.nih.gov/32950657Data on prognostic factors associated with 3-month and 1-year mortality from infective endocarditis.
Magali Collonnaz, Marie-Line Erpelding, François Alla...
https://pubmed.ncbi.nlm.nih.gov/33225027Adherence to diagnostic and therapeutic practice guidelines for suspected cardiac implantable electronic device infections.
Guillaume De Ciancio, Marie-Line Erpelding, Laura Filippetti...
https://pubmed.ncbi.nlm.nih.gov/34742672Symptomatic and Asymptomatic Neurological Complications of Infective Endocarditis: Impact on Surgical Management and Prognosis.
Christine Selton-Suty, François Delahaye, Pierre Tattevin...
https://pubmed.ncbi.nlm.nih.gov/27400273Characteristics of patients with infective endocarditis and no underlying cardiac conditions.
Aleyya Radjabaly Mandjee, Laura Filippetti, François Goehringer...
https://pubmed.ncbi.nlm.nih.gov/35604065